FDA EIR - Samsung Biologics Co., Ltd. - July 30, 2024

FDA EIR for Samsung Biologics Co., Ltd. on July 30, 2024. Product: Biologics. Access full analysis and detailed observations.

View on Dashboard

One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.

Record Summary

FDA EIR for Samsung Biologics Co., Ltd. on July 30, 2024. Product: Biologics. Access full analysis and detailed observations.

Violation Codes

FD&C Act 704(a)(4)

21 CFR 211

21 CFR 820.50

21 U.S.C. 374(a)(4)

Get More Insights

Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.

1.5M+ regulatory data points

Real-time compliance monitoring

Interactive analytics dashboard

Looking for more records? Our platform provides access to thousands of similar regulatory documents with advanced search and filtering capabilities.

Record Information

Company

Samsung Biologics Co., Ltd.

Inspection Date

July 30, 2024

Product Type

Biologics

Office

Office of Pharmaceutical Manufacturing Assessment

People

ID: 033a5fa8-b6a6-4d39-85d9-01bb91ffa2e1

View on Dashboard

Transform Regulatory Data into Actionable Intelligence

Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.

Try KeyPedia Today

Explore our real use cases and discover our features in depth.

Subscribe to our newsletter

Get the latest updates and insights delivered to your inbox